Research To Practice | Oncology Videos Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 13, 2025
Dr. Matthew Lunning is a hematologist specializing in CAR T-cell therapy and bispecific antibodies, while Dr. Sonali M. Smith focuses on lymphoma research and treatment innovations. They discuss the complexities of logistic challenges and early referral strategies for CAR T therapies in high-risk diffuse large B-cell lymphoma (DLBCL). The conversation also highlights the effectiveness of novel agents like epcoritamab and the importance of managing toxicities. They delve into evolving treatment protocols, including the sequence of using bispecifics before CAR T for optimal outcomes.
AI Snips
Chapters
Transcript
Episode notes
The Hidden Logistical Hurdles To CAR T
- Dr Matthew Lunning recounted logistical and insurance hurdles that cause patients to drop out before CAR T-cell therapy.
- He described the 'brain-to time' between referral and receipt of CAR T as the real denominator for access.
CAR T Beats Real-World Standard Of Care
- Zuma-7 and TRANSFORM showed CAR T improved event-free survival versus real-world standard of care, not just transplant.
- Earlier referral to CAR T may benefit patients not achieving early responses to frontline chemo.
CR Drives Durability In Follicular Lymphoma
- In follicular lymphoma achieving a CR after CAR T correlates with durability of response.
- Timing matters: using CAR T when disease is behaving aggressively yields better long-term control.